Project Details
Description
Dompe farmaceutici s.p.a. - REP0121, A multicenter, randomized, doubleblind, placebo-controlled phase 2 study to assess the efficacy and safety of oral reparixin in cancer related fatigue in patients with locally advanced or metastatic breast cancer und
| Status | Active |
|---|---|
| Effective start/end date | 7/8/21 → 7/31/26 |
Funding
- DOMPE S.P.A
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.